Study summary
A pill that protects podocytes lowered proteinuria in a third of patients
35%proteinuria response across doses, vs 7% with placebo
What was tested
BI 764198, a once-daily pill that blocks TRPC6, a calcium channel whose overactivity damages podocytes (the kidney filter cells injured in FSGS), against placebo for 12 weeks.
What they found
- A 25% or greater drop in proteinuria occurred in 35% across all doses vs 7% with placebo (44% at 20 mg).
- Side effects were similar to placebo.
What it means
The first evidence that a podocyte-targeted drug works in FSGS; a phase 3 trial has started.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.